Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination.

Strezova, Ana; Diez-Domingo, Javier; Al Shawafi, Kamal; Tinoco, Juan Carlos; Shi, Meng; Pirrotta, Paola; Mwakingwe-Omari, Agnes

Strezova, Ana; Diez-Domingo, Javier; Al Shawafi, Kamal; Tinoco, Juan Carlos; Shi, Meng; Pirrotta, Paola; Mwakingwe-Omari, Agnes.

Afiliação

Strezova A; GSK, Rixensart, Belgium.
Diez-Domingo J; FISABIO Fundación para el Fomento Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Valencia, Spain.
Al Shawafi K; Modis, Belgium c/o GSK, Wavre, Belgium.
Tinoco JC; Hospital General de Durango, Durango, Mexico.
Shi M; GSK, Rockville, Maryland, USA.
Pirrotta P; GSK, Wavre, Belgium.
Mwakingwe-Omari A; GSK, Rockville, Maryland, USA.

Open Forum Infect Dis ; 9(10): ofac485, 2022 Oct.

Article em En | MEDLINE | ID: mdl-36299530

Palavras-chave

adjuvanted recombinant zoster vaccine; immune response persistence; long-term efficacy; long-term safety

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google